Kuhlman Justin J, Alhaj Moustafa Muhamad, Jiang Liuyan, Wang Jing, Gupta Vivek, Tun Han W
Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA.
Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
Blood Lymphat Cancer. 2022 Apr 14;12:23-29. doi: 10.2147/BLCTT.S360442. eCollection 2022.
Primary central nervous system lymphoma (PCNSL) carries a dismal prognosis in elderly patients above 70 years of age with a median overall survival of 6 months. Novel therapeutic agents are urgently needed to improve survival outcomes in this age group. We describe the clinical presentation, diagnostic workup, and treatment outcome in two 80-year-old patients diagnosed with PCNSL who were treated with ibrutinib therapy. Both patients remain in complete remission following treatment with ibrutinib therapy. One patient is currently 4 years and the other is 2 years and 9 months from the time of initial diagnosis. We suggest that ibrutinib therapy has significant therapeutic activity against PCNSL in the newly diagnosed setting and should be evaluated in a clinical trial as part of front-line therapy, especially in elderly patients.
原发性中枢神经系统淋巴瘤（PCNSL）在70岁以上老年患者中的预后不佳，中位总生存期为6个月。迫切需要新型治疗药物来改善该年龄组的生存结果。我们描述了两名80岁确诊为PCNSL并接受依鲁替尼治疗的患者的临床表现、诊断检查和治疗结果。两名患者在接受依鲁替尼治疗后均处于完全缓解状态。一名患者自初次诊断起已存活4年，另一名患者已存活2年9个月。我们认为，依鲁替尼治疗在新诊断的PCNSL患者中具有显著的治疗活性，应在临床试验中作为一线治疗的一部分进行评估，尤其是在老年患者中。
